Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.
Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.
Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).
Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.
Using a life–years gained approach to select patients for lung cancer screening could maximize its benefits for current and ex-smokers who have both a high risk for lung cancer and a long life expectancy, US research suggests.
Receipt of the Bacillus Calmette-Guérin vaccine may reduce the risk for developing lung cancer, suggests a secondary analysis of a clinical trial conducted in American–Indian and Alaska Native populations.
Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.
The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.
An electronic nose can predict if patients with advanced non-small-cell lung cancer will respond to immune checkpoint inhibitor therapy by analyzing the composition of volatile organic compounds in patients’ exhaled breath, say researchers.
IASLC 2019 World Conference on Lung Cancer: Independent satellite symposium
Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn Access the scientific summary with video highlights and faculty interviews, including take-home messages from the symposium.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
